Core Viewpoint - Pfizer is facing significant challenges that could impact its attractiveness as an investment, particularly in relation to its dividend yield and upcoming patent expirations [1] Group 1: GLP-1 Drug Development - Pfizer's stock has fallen over 50% from its 2021 highs, partly due to its lack of a GLP-1 drug, which is crucial for diabetes management and weight loss [2] - The company previously had an internal GLP-1 candidate that was dropped, leaving it behind competitors like Eli Lilly and Novo Nordisk, which have successful GLP-1 drugs on the market [3] - Pfizer is attempting to catch up by acquiring a company with a promising GLP-1 pipeline and has agreed to distribute a GLP-1 pill for a Chinese company pending approval [3][4] Group 2: Patent Expirations - Pfizer is approaching key patent cliffs, with its oncology drug Ibrance expected to face generic competition in 2027, followed by cardiovascular drugs Eliquis and Vyndaqel in 2028 [5] - The timing of new drug development and patent expirations does not always align, but 2026 is critical as it is the last year before revenues from key drugs may start to decline [6] Group 3: Dividend Concerns - Pfizer's dividend payout ratio is around 100%, raising concerns about its ability to sustain dividends amidst setbacks in GLP-1 development and upcoming patent cliffs [7] - Although dividends are paid from cash flow rather than earnings, the high payout ratio, combined with recent acquisitions and the capital-intensive nature of the pharmaceutical sector, adds to the worry [8]

Core Viewpoint - Speculation regarding a potential acquisition of ABIVAX by Eli Lilly has led to significant share price movements, despite the company's CEO dismissing these rumors as unfounded noise [1][2][3]. Group 1: Share Price Movement - ABIVAX shares experienced a dramatic increase of over 2,000% from July to December 2025, peaking at $145 on December 24 before settling at $118 after the French government dismissed the acquisition rumors [2]. Group 2: Company Clarifications - ABIVAX's CEO, Marc De Garidel, stated that no formal discussions regarding a takeover have occurred and emphasized that any informal conversations do not comply with regulatory requirements [1][3]. - De Garidel highlighted that a public deal announcement would precede any engagement from foreign investment oversight, indicating a structured approach to potential investments [3]. Group 3: Company Focus and Financial Needs - The company is advancing its therapeutic program, obefazimod, which is well-funded through Q4 2027, but still requires additional financing as indicated by discussions with potential investors at the JPMorgan Healthcare conference [3]. - ABIVAX develops antiviral and vaccine products targeting various diseases, including chronic hepatitis B, Ebola, dengue, and ulcerative colitis, as well as commercial vaccines for typhoid, meningococcal, and leptospirosis [4].

Core Viewpoint - Wall Street's main averages experienced a decline as investors assessed recent company earnings and focused on the implications of Kevin Warsh's selection as Federal Reserve chair [2]. Group 1: Company Earnings - Major S&P 500 companies, including Alphabet (GOOGL), Amazon (AMZN), AMD (AMD), Merck (MRK), and Pfizer (PFE), are set to release their quarterly financial results in the week ending February 6 [4]. - Earnings spotlight for Monday includes Palantir (PLTR) and Walt Disney (DIS) [5]. - Earnings spotlight for Tuesday features AMD, Merck, PepsiCo (PEP), Amgen (AMGN), and Pfizer [5]. - Earnings spotlight for Wednesday includes Alphabet and Eli Lilly [5]. Group 2: Economic Data Releases - Key economic data releases include S&P Global Manufacturing PMI, ISM Manufacturing Prices, and ISM Manufacturing PMI for January on Monday [3]. - JOLTS Job Openings data for December is scheduled for release on Tuesday [3]. - ADP Nonfarm Employment Change, S&P Global Services, and Composite PMI for January will be released on Wednesday [3]. - Initial Jobless Claims data is due on Thursday, while Nonfarm Payrolls and Unemployment Rate for January are set for release on Friday [3].

This could finally be the start of the drugmaker's comeback.Last year wasn't great for Novo Nordisk (NVO +0.17%). One of the biggest challenges it faced was losing ground in the all-important weight loss market to its biggest competitor, Eli Lilly.However, Novo Nordisk has a plan to get things back on track, and the company's oral Wegovy is part of that strategy. In December, Novo Nordisk earned approval for the oral version of its famous medicine, which it launched earlier this month. And so far, things ar ...

Wednesday morning, Eli Liy reports its earnings haven't been the propellant here. What drives the stock are new reports on GOP-1 clinical trials, but Lily could announce some new data and that could get the stock rolling. At the close, we hear from the best stock in the business, at least by my count, the one that we bought back, the charable trust, because I just did I had such sellers from worse here, Alphabet.Yeah, this is a company that many wrote off as the least of the magnificent seven because they f ...

Core Insights - Novo Nordisk received regulatory approval for its weight loss pill, the first oral GLP-1 drug, presenting a significant growth opportunity for the company [1] - The stock of Novo Nordisk has increased by approximately 26% as of January 26, 2026, outperforming the S&P 500, which rose by only 1.5% [2] - Demand for the Wegovy pill has been strong, with 18,410 prescriptions in the U.S. during its first full week of launch [3] Financial Performance - Novo Nordisk's growth rate is expected to improve in 2026 due to strong demand for its weight loss pill, following a previous reduction in sales growth guidance from 13%-21% to 8%-14% due to competition [4] - The company's stock fell by 41% last year, but it is currently trading at a price-to-earnings (P/E) multiple of 17, which is significantly lower than rival Eli Lilly's P/E of over 50, indicating potential for a rally [5] Market Outlook - There is potential for further stock price increases for Novo Nordisk in 2026, suggesting that it may still be an opportune time for investment [6] - Despite the positive outlook, Novo Nordisk was not included in a list of the top 10 stocks recommended by an analyst team, indicating some caution among analysts [7]

Core Viewpoint - Investors are expected to focus on Viking Therapeutics' progress with VK2735, a dual agonist for obesity treatment, during the upcoming Q4 and full-year 2025 results announcement [1] Company Overview - Viking Therapeutics is developing VK2735 for obesity treatment, with no marketed drugs currently in its portfolio, leading to no expected revenues for the upcoming quarter [2] - The Zacks Consensus Estimate for Q4 earnings is a loss of 89 cents per share [2] Pipeline Development - VK2735 is being studied in multiple late-stage studies, including VANQUISH-1 and VANQUISH-2, for both oral and subcutaneous formulations [5] - The VANQUISH-1 study, completed in November 2025, evaluates VK2735 in obese adults with weight-related co-morbid conditions, while VANQUISH-2 focuses on obese or overweight adults with type II diabetes [6][7] Competitive Landscape - Eli Lilly and Novo Nordisk dominate the obesity treatment market with their GLP-1 injections, which may increase competitive pressure on Viking Therapeutics [9] - Novo Nordisk recently launched an oral version of Wegovy, and an FDA decision on Lilly's oral obesity pill is expected in the first half of 2026 [9] Financial Performance - Viking Therapeutics has a history of earnings surprises, missing estimates in the last four quarters with an average negative surprise of 21.66% [11] - The company currently has an Earnings ESP of 0.00%, indicating no expected earnings beat for the upcoming report [12][13] Future Updates - Further updates on VK2735, as well as the company's NASH and X-ALD programs, are anticipated during the upcoming earnings call [10][8]

I recommend buying the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM ). This is my first article about a thematic ETF of this type. However some time ago I wrote my investment thesis about Eli Lilly, and theMore than 7 years of experience in equity analysis in LatAm. We provide our clients with in-depth research and insights to help them make informed investment decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to init ...

Core Viewpoint - Recursion Pharmaceuticals is a small-cap biotech aiming to transform drug development through artificial intelligence, but has faced significant challenges and limited success so far [1] Group 1: Clinical Progress - Recursion Pharmaceuticals employs an AI-powered system to test clinical compounds, potentially increasing success rates and reducing costs associated with preclinical studies [2] - The company’s most advanced candidates are in mid-stage studies, with expected data readouts for REC-1245 (a cancer medicine) in the first half of the year and REC-102 (for hypophosphatasia) in the second half [3][4] Group 2: Market Competition - The company faces increasing competition, particularly from Eli Lilly, which is developing a powerful supercomputer for drug development [5] - Eli Lilly has significantly more resources, including cash and clinical trial data, which could hinder Recursion's ability to license its AI models to other drugmakers [6]

Core Insights - Halozyme Therapeutics is expanding its portfolio with the acquisition of Hypercon and Surf Bio, enhancing its capabilities in subcutaneous (SC) drug delivery technologies [4][5][6] - The company expects significant revenue growth, with preliminary 2025 total revenue estimates between $1.385 billion and $1.4 billion, representing a 36% to 38% increase over 2024 [8] - Halozyme has raised its 2026 guidance, projecting total revenue between $1.71 billion and $1.81 billion, with royalty revenue between $1.13 billion and $1.17 billion [17] Acquisition and Technology Expansion - The acquisition of Surf Bio adds a second hyperconcentration technology, which is expected to be clinic-ready by the end of 2027 or early 2028 [4][7] - Hypercon technology is anticipated to be clinic-ready in 2026, with two partners expected to initiate Phase I studies by the end of 2026 [5][7] - The company now has three royalty-bearing SC delivery technologies, expanding its opportunity set into the mid-2040s [5][6] Financial Performance and Projections - Halozyme's 2025 royalty revenue is projected to be between $865 million and $870 million, reflecting a growth of 51% to 52% over 2024 [8] - For 2026, the company expects to exceed $1 billion in royalty revenue, a year earlier than previously projected [9] - Long-term projections indicate total revenue exceeding $2 billion by 2028, with royalty revenue between $1.46 billion and $1.51 billion, representing a CAGR of 26% to 28% from 2024 to 2028 [11] Product Development and Market Strategy - The company anticipates six new ENHANZE products entering Phase I in 2026, increasing the development portfolio to 13 products [13] - Major product drivers include DARZALEX and VYVGART Hytrulo, with projected sales of $14.3 billion and $4.15 billion respectively for 2025 [13] - Halozyme is exploring additional M&A opportunities to enhance its drug delivery technology and revenue growth [15] Profitability and Operational Efficiency - Halozyme aims for a gross margin above 80% and an operating margin greater than 60% during the 2026–2028 period [12] - The company projects free cash flow to exceed 70% of EBITDA, indicating a strong focus on operational efficiency [12]